ArticlePharmacoEconomics - open2024

Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

Sydney George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.